Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
USE CASES
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
PatSnap Eureka Desktop
NEWAnalytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
NEWServices professionnels
Cabinets d'avocats
Sciences de la vie
Haute technologie
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport Analyse BD's 1,267-patent innovation journey from needle safety to AI diagnostics. Three waves, key trends, and what drives BD's medtech strategy through 2026.
Article | Rapport Biopharma BD teams: Identify lucrative licensing opportunities using AI-powered patent analytics. Accelerate asset evaluation & diligence. Request a demo.
Article | Rapport Identify licensing opportunities with patent analytics. Patsnap Eureka Life Science helps BD teams find novel drug assets, assess IP, & benchmark competitors faster. Book a demo.
Article | Rapport Struggling to link competitor pipelines to patent families? Patsnap Eureka Life Science unifies biopharma data, extracting IP insights for CI teams. Book a demo.
Article | Rapport Master white space analysis in drug discovery with AI. Patsnap Eureka Life Science reveals therapeutic gaps, unmet needs, and competitive intelligence fast. Explore the platform.
Article | Rapport Discover top pharma patent expiration tools. Navigate regulatory exclusivity & FTO with AI-powered platforms like Patsnap Eureka Life Science. Accelerate deals—Request a demo.
Article | Rapport Master complex biologics FTO analysis with this expert guide. Learn essential steps and how AI-powered patent intelligence accelerates your workflow. Request a demo.
Article | Rapport Master patent search for chemically modified sequences like GalNAc & LNA. Discover how Patsnap Eureka Life Science's AI platform reduces FTO risk. Book a demo today.
Article | Rapport Monitor competitor monoclonal antibody patents with AI. Get proactive insights, extract deep data, and compare assets for strategic mAb competitive intelligence. Request a demo.
Article | Rapport IP professionals need biosequence search & patent legal status. Patsnap Eureka Life Science unifies both for FTO, prior art, and defensible IP opinions. Book a demo.
Article | Rapport How does tezepelumab's TSLP inhibition differ from IL-33 blockade (itepekimab, astegolimab) in phenotype coverage, clinical efficacy, and atopic march pipeline potential?
Article | Rapport APOE ε4 genotype ARIA risk multipliers and clinical decision framework for lecanemab and donanemab prescribing in Alzheimer's disease treatment.
Article | Rapport How do FXIa inhibitors asundexian and milvexian compare to apixaban and rivaroxaban on bleeding risk and efficacy? Patent and clinical trial evidence analysed.
Article | Rapport How do Tarlatamab and Elranatamab differ from gamma-delta T-cell therapies in TME penetration, cytokine release risk, and MHC-I resistance? A mechanistic analysis.
Article | Rapport How do patient population differences and I² heterogeneity (0%–95%) across five Lecanemab/Donanemab trials affect meta-analysis reliability and clinical applicability?